AdvanDX finds $15M in third VC round

France's BioMerieux has signed on as an investor for AdvanDX, a diagnostics company based in Woburn, MA, contributing to a $15 million Series C round for the company. The money is earmarked for R&D and marketing costs. AdvanDX is marketing its PNA FISH test, a rapid diagnostic for blood infections.

- here's the release on the round

Suggested Articles

Tufts scientists discovered that two anti-seizure drugs can lessen the development of brain defects caused by nicotine exposure in frogs.

Merck will apply its vaccine capabilities to an asset based on Themis’ measles vector platform that is set to enter the clinic this year.

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.